BioNTech More Positive About Sales of Corona Vaccine

Biotech company BioNTech is more positive about sales of its corona vaccine this year. The group previously assumed total sales of between 13 and 17 billion euros.

 

In a new estimate, the company now counts on at least 16 billion euros. In addition to continued demand for the vaccine, the German company is also benefiting from higher prices.

In a statement, BioNTech reports that sales will be lower than last year when the vaccine yielded 19 billion euros. The company announced that in mid-October had billed approximately 300 million doses of its omicron-modified vaccines.

However, BioNTech’s quarterly results were well below those of the same quarter last year when vaccination campaigns were in full swing. Turnover in the third quarter fell by 43 percent to just under 3.5 billion euros. Net profit fell by 44 percent to 1.8 billion euros.

The German biotech company developed the vaccine together with the American pharmaceutical company Pfizer. Last week, it raised its forecast by $2 billion to $34 billion for vaccine sales this year.